paulsbest
7年前
$SGBI - FDA GRANTS FAST TRACK DESIGNATION TO GRANULOX
FDA FAST Track Designation
FDA grants FAST TRACK DESIGNATION
Witten, November, 13, 2017: Infirst Healthcare Ltd has announced that the United States (US) Food and Drug Administration (FDA) has granted Fast Track designation to Granulox 10% haemoglobin spray (porcine haemoglobin) for the treatment of diabetic foot ulcers (DFUs). It is the first and only haemoglobin spray to receive Fast Track designation – a process designed by the FDA to facilitate the development, and expedite the review of, new therapies to treat serious conditions and fill an unmet medical need.
Wowsers! $$$ Big gainer this one! $$$ GLTA
funnyG986
8年前
SGBI great news unnoticed 0.02 x 0.03
http://www.finanznachrichten.de/nachrichten-2016-12/39507407-dgap-news-sangui-biotech-international-inc-sastomed-schliesst-vertriebsvereinbarung-fuer-die-tuerkei-granulox-erhaelt-produktzulassung-in-kuwe-016.htm
DGAP-News: Sangui BioTech International Inc. / Key word (s): Miscellaneous Sangui BioTech International Inc .: - SastoMed signs distribution agreement for Turkey; - Granulox receives product approval in Kuwait
21.12.2016 / 10:43 The issuer is solely responsible for the content of this announcement.
Sangui BioTech: - SastoMed signs distribution agreement for Turkey
- Compulsory fixed-dose quantity agreed - Granulox receives product approval in Kuwait
Witten, 21.12.2016:
Following the successful integration of the sales regions South East Asia and Russia in October this year, SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox, has now also entered into a sales partnership with Turkey. With SAF Pharma Health Services SA (SAF), a powerful partner for the introduction of Granulox in this important territory was won. As was already the case with Zuellig Pharma for Southeast Asia and the MDP Group for Russia, it was also possible to agree with the SAF guaranteed fixed purchase rate for Turkey. In the course of the next five years, the SAF will, in line with the anticipated course of the approval and reimbursement procedure, obtain annually increasing minimum volumes with a total volume in the high five-digit range. "With Turkey, a further, promising sales region with 78 million inhabitants could be awarded to an ambitious partner. The fact that minimum sample sizes could be agreed again confirms our partners' trust in the successful market launch of Granulox," says Michael Sander , Managing Director of SastoMed GmbH.
In December, the product approval procedure for Granulox in Kuweit was successfully completed. The product approval is essential for a successful distribution of Granulox. Granulox was therefore approved for the first time in an Islamic state. "This approval makes it clear that the marketing of granulox is also possible in countries which, due to religious practices, have reservations about products containing porcine ingredients. The authorities have convinced and assisted on the ground in terms of clinical and health care "This is an important precedent that supports our efforts in other Muslim countries such as Indonesia," says Michel Sander.
Sangui BioTech International, Inc. ("SGBI") is a holding company whose shares are traded on OTCQB (www.otcmarkets.com: SGBI) and in the free circulation of the stock exchanges in Berlin and Hamburg-Hannover (www.boersenag.de: SBH) will. Its business purpose is to raise funds and secure access to the capital market for Sangui Group companies. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui Biotech International, Inc.
Further information: Sangui Biotech International, Inc. Thomas Striepe Fax: +49 (2302) 915 191 E-Mail: info@sangui.de
Some statements in this release are forward-looking statements, estimates of future operating results or financial circumstances, or other forward-looking statements. Whether these statements are true depends on many known risks, unexpected developments, uncertainties or other factors that could lead to the fact that the future development actually deviates significantly from these future expectations. Forward-looking statements are based on a variety of variables and assumptions. A number of important risks that could lead to deviations from the statements made here include, but are not limited to, the ability of the company to obtain sufficient funding for future operations. Words such as "believe", "estimate", "plan", "expect", "intend" or "prediction", other forms of these words or comparable expressions are intended to indicate that these are forward-looking statements. The company does not assume any obligation beyond the statutory provisions to correct the statements made here or to adapt them to changed conditions and developments.
21.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer / publisher is responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial / Corporate News and Press Releases. Media archive at http://www.dgap.de
532201 21.12.2016
ISIN US80105B1017
AXC0065 2016-12-21 / 10: 44
funnyG986
8年前
SGBI news 11/25/2016
Sangui BioTech International Inc .: New expert consensus underscores the outstanding effect of granulox in chronic wounds
Sangui BioTech International Inc. / Key word (s): Miscellaneous Sangui BioTech International Inc .: New expert consensus underlines the outstanding effects of granulox on chronic wounds
25.11.2016 / 11:19 The issuer is solely responsible for the content of this announcement.
Sangui BioTech:
- New expert consensus underlines the outstanding effect of granulox in chronic wounds
Witten, 25.11.2016:
In the edition 5/2016 of the specialist magazine "Wundmanagement" (Wundmanagement 2016; 5: 276-284), the official notification body of the initiative Chronic Wounds eV (ICW eV), the "expert conscience is to practice-relevant aspects of the wound therapy with a hemoglobin spray "Has been published. This publication is another proof that the wound spray Granulox contributes to a faster wound healing.
The recommendation was recommended by well-known experts from the DACH region. Prof. Dr. med. Joachim Dissemond, board member of ICW eV and head of ICW-certified dermatological wound care at the university hospital in Essen, Veronika Gerber, first chairman of ICW eV, Prof. Dr. Knut Kröger, deputy chairman of ICW As well as specialist author and speaker for wound care concepts Kerstin Protz.
Austria is represented by Prim. Univ. Prof. Dr. med. Robert Strohal and the Wound Care Manager Peter Kurz. PD Dr. med. Severin Läuchli, acting president of the European Wound Management Association (EWMA) and head of dermatology at the University of Zurich and Siegfried Uttenweiler are responsible for the Swiss vote.
The outstanding contribution not only considers the well-known methods and possible product combinations of Granulox. He is also dedicated to presenting the novel MOIST concept for the local treatment of chronic wounds. For the first time, oxygen as well as further substances or methods with a supporting effect, such as growth factors, are included in the existing concept for the local therapy of chronic wounds. This is a milestone for the importance of oxygen in the area of ??wound healing. The expert consensus also shows a clear and precise application algorithm for granulox. Accordingly, Granulox should be used every three days for both acute and chronic wounds that have not decreased by at least 40% after four weeks of conventional treatment and thus meet the criterion of slowed wound healing. Healing progress should be reevaluated at 4-week intervals or in the event of complications.
It is clear from the expert consensus that granulox is well suited to provide wounds with additional oxygen. In addition, the healing processes can be promoted in hypoxic wounds, especially if a sufficient improvement in wound healing by standard therapies could not be achieved. Thus the publication once again shows that Granulox should be integrated as a treatment method in the care of chronic wounds.
"We are delighted that such a high-caliber international expert group emphasizes the role of Granulox in modern wound treatment and calls for a systematic use in ill-healing wounds," commented Michael Sander, Managing Director of Sastomed GmbH, to whom Sangui BioTech GmbH has the worldwide distribution rights For the wound spray granulox. The full article can be downloaded at http://granulox.de/downloads/Wundmanagement_5_2016_Konsensus_DE.pdf.
Sangui BioTech International, Inc. ( "SGBI") is a holding company whose shares are traded on OTCQB (www.otcmarkets.com: SGBI) and in the free circulation of the stock exchanges in Berlin and Hamburg-Hannover (www.boersenag.de: SBH) will. Its business purpose is to raise funds and secure access to the capital market for Sangui Group companies. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui Biotech International, Inc.
Further information: Sangui Biotech International, Inc. Thomas Striepe Fax: +49 (2302) 915 191 E-Mail: info@sangui.de
http://www.finanznachrichten.de/nachrichten-2016-11/39286960-dgap-news-sangui-biotech-international-inc-neuer-expertenkonsens-unterstreicht-die-herausragende-wirkung-von-granulox-bei-chronischen-wunden-deuts-016.htm
funnyG986
8年前
SGBI news today huge $$$ revenue coming with minimum purchase order from Asia
Sangui BioTech: SastoMed Enters into Sales Agreements for Southeast Asia, Poland and Russia
Last update: 02/11/2016 6:00:01 am
-- Firm purchase commitments agreed
WITTEN, Germany--(BUSINESS WIRE)--November 02, 2016--
SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox, concluded a comprehensive licensing and sales agreement for eight Southeast Asian States with Zuellig Pharma, Singapure (www.zuelligpharma.com) one of the world's leading service providers of the pharmaceuticals. Zuellig Pharma is responsible for market launch and distribution of Granulox in the territories of Hong Kong, Singapore, Thailand, Malaysia, Taiwan, Vietnam, Indonesia and the Philippines. In addition to the complete processing and financing of admission in the individual territories, Zuellig Pharma has committed itself to the purchase of significant quantities of Granulox within the next five years. Furthermore, two high -- performance distribution partners could be bound: Hexanova Sp.z.o.o. for Poland (www.hexanova.pl) and MDP Group for Russia (www.mdp-group.net). In both cases, minimum purchase commitments were also been agreed upon.
"With these agreements, we have succeeded in pushing forward into new dimensions. Inside the newly acquired sales areas, more than half a billion people live. We have now reached an important milestone on our path to global expansion. In addition to the quantitative dimension, the qualitative contract value of the agreements was also increased. In the past five years, Granulox has proven in field that it keeps what it promises on paper. When granting new territories, we now benefit from the appreciation Granulox has now gained. For instance, Zuellig Pharma for Southeast Asia and the MDP Group for Russia, two veritable global players with a corresponding sales force and financial strength, could be obtained for Granulox. Both partners have committed themselves to realize the necessary regulatory approvals and subsequent market launch of Granulox in the respective territories. Guaranteed purchase commitments were agreed with both partners. The annual minimum purchase quantities fixed within the next five-year period up to 2021 are based on the time-staggered progress of the product launches expected by Zuellig Pharma and MDP Group. Starting with the approval of Granulox, followed by the starts of the marketing campaigns and Granulox's positive sales development, specific verifiable milestones were established together with our partners for the individual territories. The cumulative purchase commitments for quantities over the next five years are well in the middle six-digit range. On the one hand, this minimum order gives us further planning certainty and ensures that we achieve our ambitious goals. On the other hand, this fact underscores the strong confidence our partners have in the future success of the cooperation with SastoMed ", explains Michael Sander, CEO of Sastomed GmbH.
"We congratulate SastoMed on these breakthroughs. After the inclusion of Granulox in the Drug Tariff of the British NHS at the beginning of October 2016, SastoMed herewith has reached further trend-setting successes. Sangui as licensors for Granulox will definitively benefit from these success. In this regard, the year 2016 can be described as very successful ", says Thomas Striepe, President and CEO of Sangui BioTech International Inc.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
DoublePlusGood
8年前
SGBI-NEWS British National Health Service NHS Granted Wound Spray Granulox Reimbursement
October 05, 2016 05:32 AM Eastern Daylight Time
WITTEN, Germany--(BUSINESS WIRE)--The SastoMed GmbH has announced that the British National Health Service (NHS) has taken the wound spray Granulox licensed by Sangui to SastoMed GmbH on the list of reimbursable products under a discrete category (NHS Drug Tariff Part IX) effective October 01, 2016. The NHS provides to each resident of the UK medical care in the primary (general practitioner GP) and secondary level (hospitals) free of charge. Furthermore, in a declaration recently published the Scottish Health Technologies Group (SHTG - a division of NHSScottland) has clearly recommended the application of Granulox to all doctors working for NHSScottland because of Granulox’ efficacy and marked cost savings of several thousand British pounds proved by several studies.
Michael Sander, Managing Director of SastoMed GmbH commented: "InFirst Healthcare as our partner in the UK, has done an excellent job. Because of the convincing data submitted a worldwide respected and efficient health care system such as the NHS has not only appreciated the significant improvement in the quality of life for millions of patients suffering from chronic wounds, but also confirmed the significant cost reduction potential by using Granulox. We see this as a breakthrough success, which will integrated Granulox in modern wound treatment system not only in Great Britain. In parallel InFirst is working hard on the approval for the US market - even for that the extensive data from England constitute an important basis ".
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
Link:. http://www.businesswire.com/news/home/20161005005572/en/Sangui-BioTech-British-National-Health-Service-NHS
DoublePlusGood
8年前
The German version of this stock manages to stay above .03 and we're at .006. The two stocks have nearly identical share structures.
SGBI share structure from most resent Q:
As of May 23, 2016, there were 165,372,503 shares of the issuer's Common Stock, no par value, issued and outstanding.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11405136
Share structure of German SBH according to Bloomberg:
SHARES OUTSTANDING (M)
165.373
http://www.bloomberg.com/quote/SBH:GR
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Renee
3週前
nickeli54
3年前
gwat1979
7年前
Prinz18
8年前
jpast198
8年前
